Dr. Ethan Russo: Cannabis & Endocannabinoid System Breakthroughs | CannabizMD 2021 Keynote

This is the keynote presentation from the CannabizMD 2021 Cannabis Science and Policy Forum, featuring Dr. Ethan Russo, one of the world's leading authorities on cannabis medicine.

About This Keynote:
Dr. Russo presents groundbreaking research on two critical conditions reshaping cannabis therapeutics:
Cannabinoid Hyperemesis Syndrome (CHS) - The largest genetic study to date, examining 585 respondents and identifying five statistically significant genetic mutations predicting susceptibility to this mysterious condition affecting chronic cannabis users.

Fibromyalgia Research - Investigating whether autoantibodies attacking cannabinoid receptors could explain fibromyalgia, potentially providing the first laboratory test for a condition affecting 10 million Americans.

About Dr. Russo:
Board-certified neurologist, psychopharmacology researcher, and Founder/CEO of CReDO Science. Former Senior Medical Advisor to GW Pharmaceuticals for clinical trials leading to Sativex and Epidiolex. Author of the landmark paper "Taming THC: Potential Cannabis Synergy and Phytocannabinoid-Terpenoid Entourage Effects." 30+ years of cannabis research with 50+ peer-reviewed publications.

Learn how genetics predict adverse cannabis reactions, the Clinical Endocannabinoid Deficiency theory, and evidence-based approaches to cannabis therapeutics from one of the field's pioneering researchers.

About CannabizMD:
CannabizMD is a leading provider of evidence-based cannabis science and policy education, including workforce development programs, training for industry professionals, and education for healthcare providers. Through partnerships with world-renowned experts like Dr. Russo, CannabizMD offers professional development programs that advance scientific understanding of cannabis therapeutics and state and federal regulations.